Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Exclusion Criteria

• •A known hypersensitivity to albuterol or any of the excipients in the formulations.
• •History of a respiratory infection or disorder that has not resolved within 1 week preceding the Screening Visit (SV).
• •History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.
• •Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV.
• •Hospitalization due to asthma exacerbation 2 or more times in the past year
• •Initiation of immunotherapy or dose escalation during the study period